Disease Domain | Count |
---|---|
Neoplasms | 2 |
Top 5 Drug Type | Count |
---|---|
Fusion protein | 1 |
Synthetic peptide vaccine | 1 |
Target |
Mechanism LAG3 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism CD3 modulators [+3] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism E7 modulators [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date17 Jul 2023 |
Sponsor / Collaborator |
Start Date01 Jun 2023 |
Sponsor / Collaborator |
Start Date22 May 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Eftilagimod alpha ( LAG3 x MHC II ) | Metastatic breast cancer More | Phase 3 Clinical |
HLA-A2 peptides(Immutep) ( CD3 x HLA class I antigen x MAGEA3 ) | Melanoma More | Phase 2 Clinical |
IMP-361 ( HPV E7 ) | Human Papillomavirus Infection More | Pending |